Oral Pre-Exposure Prophylaxis (TDF/FTC and TAF/FTC): Pharmacology, Landmark Trials, and Real-World Impact

1. Introduction: Preventing HIV Before Exposure

Pre-exposure prophylaxis (PrEP) is the use of antiretroviral medication by HIV-negative people before potential exposure, to prevent acquisition of infection. Oral PrEP with the fixed-dose combination tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) was the first formulation to demonstrate efficacy in large randomized trials, and it remains one of the most evidence-supported biomedical prevention tools available. A second backbone, tenofovir alafenamide plus emtricitabine (TAF/FTC), was later approved as an alternative with a more favorable bone and renal profile.

This article reviews the pharmacology of oral PrEP, the landmark trials that established its efficacy, the central role of adherence, the comparative evidence for TAF/FTC, the public-health recommendations, and the implementation debates. It distinguishes confirmed trial results from implementation hypotheses and from questions that remain unresolved.

2. Mechanism and Pharmacology

TDF/FTC delivers two nucleoside/nucleotide reverse transcriptase inhibitors. Tenofovir is a nucleotide analogue of adenosine monophosphate; emtricitabine is a cytidine analogue. Both must be phosphorylated intracellularly to their active diphosphate or triphosphate metabolites. Once activated, they compete with natural deoxynucleotides and act as chain terminators when incorporated into nascent viral DNA by reverse transcriptase. If exposure occurs while adequate intracellular concentrations of these active metabolites are present in target cells, reverse transcription stalls and infection is aborted before integration.

Pharmacologically, the key feature of PrEP is that protection depends on intracellular drug concentrations in the mucosal and lymphoid tissues where exposure occurs, not merely on plasma levels. Tenofovir diphosphate and emtricitabine triphosphate have long intracellular half-lives in CD4+ T cells and other targets, which allows daily dosing to sustain protective concentrations and explains why coitally-timed or on-demand dosing can also work for some populations. Tenofovir alafenamide (TAF) is a different prodrug that achieves higher intracellular and lower plasma tenofovir concentrations than TDF, which reduces exposure of renal tubular cells and bone and is the basis for its improved safety profile.

Several practical pharmacological points follow from this. Tenofovir is eliminated renally, so drugs that compete for renal tubular secretion can raise its plasma levels, and reduced kidney function slows its clearance — the basis for monitoring creatinine and estimated glomerular filtration rate. Absorption of tenofovir disoproxil fumarate is improved when taken with food, whereas tenofovir alafenamide can be taken with or without food. Because protection is a function of intracellular concentration in the tissue where exposure occurs, the dosing schedule must keep those concentrations above a protective threshold at the moment of risk; this is why daily dosing works, and why event-driven dosing requires a loading dose before exposure and continued dosing afterward.

3. Landmark Efficacy Trials

The oral PrEP literature is unusual in that a series of large randomized trials — some positive, some null — converge on a single explanatory variable: drug exposure. Trials with detectable adherence showed efficacy; trials with low adherence showed little or none.

iPrEx (Grant et al., New England Journal of Medicine, 2010) randomized men who have sex with men and transgender women to TDF/FTC or placebo. The overall reduction in HIV incidence was approximately 44%. In a nested case-control analysis, efficacy exceeded 90% among participants with detectable drug levels in their blood, establishing that the drug worked well when actually taken.

Partners PrEP (Baeten et al., New England Journal of Medicine, 2012) enrolled HIV-serodiscordant heterosexual couples in Kenya and Uganda. TDF alone reduced incidence by about 67% and TDF/FTC by about 75%. TDF2 (Thigpen et al., New England Journal of Medicine, 2012), conducted in Botswana, reported approximately 62% efficacy for TDF/FTC in heterosexual adults. The Bangkok Tenofovir Study (Choopanya et al., The Lancet, 2013) tested daily TDF in people who inject drugs and found roughly a 49% reduction overall, with higher efficacy among those with detectable drug.

Two European trials demonstrated very high efficacy with different dosing strategies. PROUD (McCormack et al., The Lancet, 2016) used daily TDF/FTC in men who have sex with men in England and reported an approximately 86% reduction in HIV incidence. IPERGAY (Molina et al., New England Journal of Medicine, 2015) used event-driven («on-demand») TDF/FTC — two tablets before sex, one tablet daily for two days after — in France and Canada and also reported roughly 86% reduction. These trial results converted oral PrEP from a promising concept into a standard-of-care intervention.

Figure values are rounded and reflect the primary reported analyses; readers should consult the original publications for confidence intervals and subgroup results. [Citation details to be verified.]

4. Adherence as the Dominant Determinant

The most important lesson across the oral PrEP trials is that adherence, not pharmacology, drove the difference between success and failure. In several trials conducted in young women in sub-Saharan Africa — including FEM-PrEP and VOICE — adherence was low, and the trials failed to show protection. When dried blood spot measurements were used to quantify tenofovir diphosphate, a clear exposure-response relationship emerged: efficacy rose steeply with increasing drug levels, approaching the high values seen in PROUD and IPERGAY among participants with consistent use.

This has two implications. First, trials that report low overall efficacy may be reporting a behavioral rather than a biological result. Second, in practice, PrEP counseling, adherence support, and objective measurement (through dried blood spots or hair samples in research settings, and through clinical follow-up in care) are integral to effectiveness. Adherence is therefore best understood as a determinant of PrEP outcomes, not a secondary consideration.

5. TAF/FTC and the DISCOVER Trial

TAF/FTC was evaluated for PrEP in the DISCOVER trial (Hare et al., The Lancet, 2019) [Citation details to be verified.], a large randomized comparison against TDF/FTC in men who have sex with men and transgender women. DISCOVER showed that TAF/FTC was non-inferior to TDF/FTC for HIV prevention. Both arms had very low HIV incidence; the trial was not powered to detect small efficacy differences and relied on a non-inferiority design. The principal advantage of TAF/FTC was a more favorable safety profile: smaller declines in bone mineral density and fewer changes in markers of renal tubular function compared with TDF/FTC. This matters for people with existing bone or kidney concerns or for long-term use. On the basis of DISCOVER, TAF/FTC was approved for PrEP in 2019, initially for populations at risk through sexual acquisition.

An important practical caveat: TAF/FTC is not recommended for individuals at risk of HIV acquisition through receptive vaginal sex, because tissue concentrations of tenofovir in the female genital tract after TAF/FTC are lower than after TDF/FTC, and the prevention evidence in that population is weaker. [Marked for verification.]

6. Recommendations and Target Populations

The U.S. Centers for Disease Control and Prevention and the World Health Organization recommend oral PrEP for people at substantial risk of HIV acquisition. The main groups identified in guidelines include men who have sex with men, HIV-serodiscordant couples, people who inject drugs, cisgender women at risk, and other individuals whose sexual or drug-use behavior places them at substantial risk. WHO has issued guidance supporting TDF/FTC as a prevention option, with an emphasis on combination prevention and voluntary, non-coerced use.

Because eligibility is behavioral rather than categorical, guidelines recommend structured risk assessment, with PrEP considered when the number of sexual partners, condom use, STI diagnoses, partner HIV status, or injection practices indicate elevated risk. PrEP is meant to be used alongside — not instead of — condoms, and as part of combination prevention that can also include testing, treatment of partners, and harm reduction.

7. Monitoring and Baseline Testing

Oral PrEP is only safe if HIV infection is excluded before and during use, because taking PrEP while already infected — or during unrecognized seroconversion — can select for drug-resistant virus. Standard practice includes a documented negative HIV test before initiation and periodically thereafter (typically every three months), renal function assessment (serum creatinine and estimated glomerular filtration rate, with the TDF-based regimen requiring particular attention to kidney function and dose adjustment decisions), screening for hepatitis B (because tenofovir and emtricitabine are active against HBV and stopping them can cause hepatitis flares), and regular screening for sexually transmitted infections.

TDF is associated with small declines in bone mineral density and with renal tubular effects; these risks are modest in most healthy users but justify periodic monitoring, particularly for those with pre-existing kidney disease, low bone density, or additional risk factors. TAF/FTC mitigates these effects but has its own considerations, including effects on lipid parameters.

8. Generic Availability and the PrEP Gap

One of the most consequential developments in PrEP delivery has been the availability of low-cost generic TDF/FTC. Generic versions became available in the United States after patent and regulatory milestones in the mid-to-late 2010s, and WHO prequalification of generic TDF/FTC enabled procurement for global programs. Generic pricing has fallen substantially, improving affordability in low- and middle-income countries. [Marked for verification.]

Despite this, a «PrEP gap» persists: the number of people who could benefit greatly exceeds the number actually using PrEP, particularly among cisgender women, people who inject drugs, and populations in low- and middle-income settings. Barriers include cost where generics are not accessible, stigma, provider unfamiliarity, clinic access, concerns about side effects, and the requirement for regular follow-up. Whether expanded community-based delivery and task-shifting can close this gap is a hypothesis under active implementation research; it is plausible but not yet fully demonstrated at scale.

9. The Risk-Compensation Debate

A recurring concern is «risk compensation»: that people using PrEP might reduce condom use or increase sexual partners because they perceive themselves protected, potentially offsetting some of the benefit. The evidence here is mixed and deserves careful framing. PrEP trials did not consistently show a large increase in condomless sex, and in several studies STI incidence remained stable or changed only modestly; however, STI rates have risen in some PrEP-using populations, a finding that may reflect increased testing and detection as much as increased risk behavior. The dominant conclusion from the trial data is that PrEP’s protective effect against HIV was not negated by behavior change. Risk compensation remains an active area of behavioral research rather than a settled worry.

10. Confirmed Findings Versus Open Questions

11. Conclusion

Oral PrEP with TDF/FTC is one of the best-documented biomedical HIV prevention tools available. Controlled trials in diverse populations showed meaningful efficacy when the drug was present; where adherence was low, the same drug failed. TAF/FTC offers a non-inferior alternative with improved bone and renal safety for populations in whom it is recommended. Guidelines from CDC and WHO define eligibility and monitoring, and generic TDF/FTC has made PrEP affordable in many settings. The remaining challenges are behavioral and structural rather than pharmacological: supporting adherence, ensuring equitable access, and closing the PrEP gap, particularly for women and people who inject drugs. Oral PrEP is highly effective in principle; its real-world impact depends on whether people can and do use it consistently.

Sources and Key Research Centers

1. U.S. Centers for Disease Control and Prevention (CDC), PrEP Guidelines — clinical practice guidelines for PrEP eligibility, monitoring, and follow-up.
2. World Health Organization (WHO) — global guidance on oral PrEP as part of combination prevention, including for key populations.
3. U.S. Food and Drug Administration (FDA) — approvals of TDF/FTC (2012) and TAF/FTC (2019) for HIV pre-exposure prophylaxis.
4. National Institute of Allergy and Infectious Diseases (NIAID), NIH — funding of iPrEx, HPTN, and the trial networks underlying oral PrEP evidence.
5. AVAC (Global Advocacy for HIV Prevention) — PrEP implementation tracking, the «PrEP gap,» and access reporting.
6. Key publications
   • Grant RM, Lama JR, Anderson PL, et al. «Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.» New England Journal of Medicine, 2010; 363(27): 2587-2599. [Citation details to be verified.]
   • Baeten JM, Donnell D, Ndase P, et al. «Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.» New England Journal of Medicine, 2012; 367(5): 399-410. [Citation details to be verified.]
   • McCormack S, Dunn DT, Desai M, et al. «Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD).» The Lancet, 2016; 387(10013): 53-60. [Citation details to be verified.]
   • Molina JM, Capitant C, Spire B, et al. «On-demand preexposure prophylaxis in men at high risk for HIV-1 infection.» New England Journal of Medicine, 2015; 373(23): 2237-2246. [Citation details to be verified.]
   • Hare CB, Coll J, Ruane P, et al. «The phase 3 DISCOVER study: daily F/TAF or F/TDF for HIV preexposure prophylaxis.» The Lancet, 2019. [Citation details to be verified.]
7. ClinicalTrials.gov — registry records for iPrEx, Partners PrEP, PROUD, IPERGAY, and DISCOVER.
8. New England Journal of Medicine, The Lancet — primary venues for the central PrEP trials.

Note: figures are rounded from primary reports; readers should confirm bibliographic details and confidence intervals against the publisher’s record. This article is an editorial scientific overview and is not a medical recommendation.